Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 0.18
ENCO's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 0.18 )
ENCO' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 0.18

Interest Coverage -10000.00
ENCO's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -10000.00 )
ENCO' s 10-Year Interest Coverage Range
Min: -1000   Max: 1000
Current: -10000

-1000
1000
F-Score: 2
Z-Score: -10.53
M-Score: -7.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -63.62
ENCO's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -63.62 )
ENCO' s 10-Year Operating margin (%) Range
Min: -63.6   Max: 19.3
Current: -63.62

-63.6
19.3
Net-margin (%) -59.13
ENCO's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -59.13 )
ENCO' s 10-Year Net-margin (%) Range
Min: -59.1   Max: 11.1
Current: -59.13

-59.1
11.1
ROE (%) -170.40
ENCO's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -170.40 )
ENCO' s 10-Year ROE (%) Range
Min: -504.4   Max: 29.2
Current: -170.4

-504.4
29.2
ROA (%) -90.50
ENCO's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -90.50 )
ENCO' s 10-Year ROA (%) Range
Min: -114   Max: 16.1
Current: -90.5

-114
16.1
ROC (Joel Greenblatt) (%) -222.80
ENCO's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -222.80 )
ENCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -222.8   Max: 266.8
Current: -222.8

-222.8
266.8
Revenue Growth (%) -28.40
ENCO's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: -28.40 )
ENCO' s 10-Year Revenue Growth (%) Range
Min: -28.4   Max: 20.6
Current: -28.4

-28.4
20.6
EBITDA Growth (%) 57.30
ENCO's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 57.30 )
ENCO' s 10-Year EBITDA Growth (%) Range
Min: -38.8   Max: 137.2
Current: 57.3

-38.8
137.2
EPS Growth (%) 20.90
ENCO's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 20.90 )
ENCO' s 10-Year EPS Growth (%) Range
Min: -18.7   Max: 74.5
Current: 20.9

-18.7
74.5
» ENCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ENCO



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 0.41
ENCO's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 0.41 )
ENCO' s 10-Year Current Ratio Range
Min: 0   Max: 0
Current: 0.41

Quick Ratio 0.26
ENCO's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 0.26 )
ENCO' s 10-Year Quick Ratio Range
Min: 0   Max: 0
Current: 0.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 67.40
ENCO's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 67.40 )
ENCO' s 10-Year Price/Net Cash Range
Min: 8.1   Max: 67.4
Current: 67.4

8.1
67.4
Price/Net Current Asset Value 4.60
ENCO's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 4.60 )
ENCO' s 10-Year Price/Net Current Asset Value Range
Min: 3.2   Max: 28.5
Current: 4.6

3.2
28.5
Price/Tangible Book 29.60
ENCO's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 29.60 )
ENCO' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 29.6
Current: 29.6

1.9
29.6
Price/DCF (Projected) 3.30
ENCO's Price/DCF (Projected) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 3.30 )
ENCO' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 6.2
Current: 3.3

0.4
6.2
Price/Median PS Value 0.10
ENCO's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 0.10 )
ENCO' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 3.6
Current: 0.1

0.1
3.6
Price/Peter Lynch Fair Value 2.70
ENCO's Price/Peter Lynch Fair Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 2.70 )
ENCO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7   Max: 2.7
Current: 2.7

0.7
2.7
Price/Graham Number 2.10
ENCO's Price/Graham Number is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. ENCO: 2.10 )
ENCO' s 10-Year Price/Graham Number Range
Min: 1   Max: 8.4
Current: 2.1

1
8.4

Business Description

Industry: »
Compare: » details
Encorium Group, Inc. formerly known as Covalent Group, Inc. was initially incorporated in August 1998 in Nevada, In June 2002, it changed state of incorporation to Delaware. The Company is a clinical research organization that engages in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries. The company offers therapeutic expertise, experienced team management and advanced technologies. The Company offers therapeutic expertise, experienced team management and advanced technologies. The Company's clients consist of some of the largest companies in the pharmaceutical and biotechnology industries. From protocol design and clinical program development, to proven patient recruitment, to managing the regulatory approval process, the Company has the resources to directly implement or manage Phase I through Phase IV clinical trials. It offers a broad range of clinical research and development services supporting Phase I through Phase IV clinical trials, such as strategic trial planning, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, quality assurance, and outsourcing of clinical staff. The Company has clinical trial experience across a wide variety of therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, women's health and respiratory medicine. The mix of projects is subject to change from year to year. It has the capacity and expertise to conduct clinical trials on a global basis. The company's services include study protocol design, clinical trials management, global data management services, biostatistics, medical and regulatory affairs, quality assurance and compliance and medical report writing. The Company's strategy is to continue to enhance its reputation as a superior provider of CRO services by providing its clients with exceptional performance ensuring that they achieve their goals on-time, on-budget and with superlative quality. The Company competes against full-service and limited service CROs, mid-sized CROs, in-house research and development departments of pharmaceutical and biotechnology companies and, to a lesser extent, universities and teaching hospitals. The Company's competitors include Quintiles Transnational Corporation, Covance, Inc., Parexel International Corporation, Icon Clinical Research and Kendle International, Inc.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide